Charles Schwab Investment Management Inc. Acquires 91,354 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Charles Schwab Investment Management Inc. increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 712,395 shares of the specialty pharmaceutical company's stock after purchasing an additional 91,354 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.29% of Supernus Pharmaceuticals worth $22,212,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC acquired a new position in shares of Supernus Pharmaceuticals during the third quarter worth approximately $791,000. Renaissance Technologies LLC raised its stake in Supernus Pharmaceuticals by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company's stock valued at $45,077,000 after purchasing an additional 351,900 shares during the last quarter. Bank of Montreal Can grew its position in Supernus Pharmaceuticals by 1,508.0% in the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company's stock worth $3,287,000 after purchasing an additional 109,088 shares during the last quarter. Candriam S.C.A. bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $3,795,000. Finally, Stephens Investment Management Group LLC raised its position in shares of Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company's stock valued at $60,246,000 after buying an additional 33,710 shares during the last quarter.

Supernus Pharmaceuticals Trading Up 0.5 %

NASDAQ SUPN traded up $0.18 on Friday, reaching $37.17. The company's stock had a trading volume of 220,365 shares, compared to its average volume of 439,903. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $39.37. The firm has a market cap of $2.05 billion, a PE ratio of 34.57 and a beta of 0.90. The business has a 50-day moving average price of $34.71 and a 200 day moving average price of $31.55.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. The business had revenue of $175.70 million during the quarter, compared to analysts' expectations of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals's quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.29) EPS. Analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on SUPN shares. Piper Sandler restated a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen restated a "buy" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 125,000 shares of the firm's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the sale, the chief executive officer now owns 926,172 shares in the company, valued at approximately $33,971,988.96. This trade represents a 11.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the sale, the director now directly owns 13,315 shares of the company's stock, valued at approximately $487,595.30. This represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 154,213 shares of company stock valued at $5,660,180. 9.30% of the stock is owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.